These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 34341132)

  • 1. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
    Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration.
    Li K; Wang J; Zhang R; Zhou J; Espinoza B; Niu N; Wang J; Jurcak N; Rozich N; Osipov A; Henderson M; Funes V; Lyman M; Blair AB; Herbst B; He M; Yuan J; Trafton D; Yuan C; Wichroski M; Liu X; Fu J; Zheng L
    J Hematol Oncol; 2024 Aug; 17(1):62. PubMed ID: 39113096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer.
    Chibaya L; DeMarco KD; Lusi CF; Kane GI; Brassil ML; Parikh CN; Murphy KC; Chowdhury SR; Li J; Ma B; Naylor TE; Cerrutti J; Mori H; Diaz-Infante M; Peura J; Pitarresi JR; Zhu LJ; Fitzgerald KA; Atukorale PU; Ruscetti M
    Sci Transl Med; 2024 Aug; 16(762):eadj9366. PubMed ID: 39196958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy.
    Zheng H; Guo B; Qiu X; Xia Y; Qu Y; Cheng L; Meng F; Zhong Z
    Bioact Mater; 2022 Oct; 16():1-11. PubMed ID: 35386324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
    Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
    Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
    ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
    Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
    Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
    Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
    Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
    Xie X; Liu J; Wang X
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.
    Metzger P; Kirchleitner SV; Kluge M; Koenig LM; Hörth C; Rambuscheck CA; Böhmer D; Ahlfeld J; Kobold S; Friedel CC; Endres S; Schnurr M; Duewell P
    J Immunother Cancer; 2019 Nov; 7(1):288. PubMed ID: 31694706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy.
    Dejmek M; Brazdova A; Otava T; Polidarova MP; Klíma M; Smola M; Vavrina Z; Buděšínský M; Dračínský M; Liboska R; Boura E; Birkuš G; Nencka R
    Eur J Med Chem; 2023 Nov; 259():115685. PubMed ID: 37567057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
    Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
    J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.